DRUG

Aucta Pharmaceuticals, Inc. ("Aucta Pharmaceuticals") launches MOTPOLY XR™ (lacosamide) extended-release capsules C-V, the first, and only once-daily formulation of lacosamide

Retrieved on: 
Monday, February 26, 2024

MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.

Key Points: 
  • MOTPOLY XR is approved for the treatment of partial-onset seizures in adults and in pediatric patients weighing at least 50 kg.
  • MOTPOLY XR is bioequivalent to Vimpat® (lacosamide) film-coated tablets, C-V and provides a new once-daily option at equivalent doses.
  • "MOTPOLY XR marks a major milestone for Aucta as our 1st branded pharmaceutical product to enter the US market.
  • To report SUSPECTED ADVERSE REACTIONS, contact Aucta Pharmaceuticals, Inc. at 1-800-655-9902 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

CMC Pictures Secured Distribution Rights for THE WHITE STORM 3: HEAVEN OR HELL

Retrieved on: 
Wednesday, June 7, 2023

BEIJING, June 7, 2023 /PRNewswire/ -- The renowned Chinese film company, CMC Pictures, announced that it has successfully acquired the distribution rights for the highest-grossing Hong Kong crime thriller franchise, THE WHITE STORM 3: HEAVEN OR HELL in US, Canada, Australia, New Zealand, UK & Ireland.

Key Points: 
  • BEIJING, June 7, 2023 /PRNewswire/ -- The renowned Chinese film company, CMC Pictures, announced that it has successfully acquired the distribution rights for the highest-grossing Hong Kong crime thriller franchise, THE WHITE STORM 3: HEAVEN OR HELL in US, Canada, Australia, New Zealand, UK & Ireland.
  • The film is directed by acclaimed filmmaker Herman Yau and follows the highly successful THE WHITE STORM 2: DRUG LORDS which grossed nearly $200 million globally in 2019.
  • THE WHITE STORM 3 is set to release in mainland China in July this year and will also be released in US, Canada, Australia, New Zealand, UK & Ireland soon.
  • CMC Pictures, the global distributor of THE WHITE STORM, is also the production company behind this summer's highly anticipated blockbuster "MEG 2 THE TRENCH", starring Jason Statham and Chinese star Wu Jing.

CMC Pictures Secured Distribution Rights for THE WHITE STORM 3: HEAVEN OR HELL

Retrieved on: 
Wednesday, June 7, 2023

BEIJING, June 7, 2023 /PRNewswire/ -- The renowned Chinese film company, CMC Pictures, announced that it has successfully acquired the distribution rights for the highest-grossing Hong Kong crime thriller franchise, THE WHITE STORM 3: HEAVEN OR HELL in US, Canada, Australia, New Zealand, UK & Ireland.

Key Points: 
  • BEIJING, June 7, 2023 /PRNewswire/ -- The renowned Chinese film company, CMC Pictures, announced that it has successfully acquired the distribution rights for the highest-grossing Hong Kong crime thriller franchise, THE WHITE STORM 3: HEAVEN OR HELL in US, Canada, Australia, New Zealand, UK & Ireland.
  • The film is directed by acclaimed filmmaker Herman Yau and follows the highly successful THE WHITE STORM 2: DRUG LORDS which grossed nearly $200 million globally in 2019.
  • THE WHITE STORM 3 is set to release in mainland China in July this year and will also be released in US, Canada, Australia, New Zealand, UK & Ireland soon.
  • CMC Pictures, the global distributor of THE WHITE STORM, is also the production company behind this summer's highly anticipated blockbuster "MEG 2 THE TRENCH", starring Jason Statham and Chinese star Wu Jing.

A Seminal Disruptive Drug Delivery Technology from Vapor Cartridge Technology LLC Proports a Paradigm Shift in the Cannabis Industry

Retrieved on: 
Tuesday, January 17, 2023

STILLWATER, Minn., Jan. 17, 2023 /PRNewswire/ -- Background: The global demand for the extracts from herbal cannabis is enormous and will grow dramatically once it becomes legalized in all of North America… which is very likely. To get the benefits of this drug, the user must ingest it into their blood stream. By far the most popular methods for ingesting the drugs are by extracting the cannabinoids et. al. using heat then inhaling the vapors. These methods require raw cannabis as a retail product and extraction by the customer using a heating process. As such there is an entire set of supply chains built around delivering dried herbal cannabis (a.k.a. flower heads) to the customer base. This age-old process is vulnerable to technological change.

Key Points: 
  • It is easy to see how his technology will result in a paradigm shift in the entire cannabis industry.
  • Vapor Cartridge Technology LLC filed a PCT application for the invention with the European Patent Office on July 9, 2020.
  • NOTE: Vapor Cartridge Technology LLC was recently granted (Nov 15, 2022) a U.S. Patent (DRUG DELIVERY SYSTEM WITH STACKABLE SUBSTRATES U.S. 11,497,249)!
  • Vapor Cartridge Technology LLC is currently seeking licensing opportunities for this patent portfolio and have launched data rich website ( https://vaporcartridgetechnology.com ) towards this objective.

AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosis

Retrieved on: 
Thursday, December 29, 2022

AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS

Key Points: 
  • AB SCIENCE HAS RECEIVED APPROVAL FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) TO INITIATE THE CONFIRMATORY PHASE 3 STUDY WITH MASITINIB IN THE TREATMENT OF PROGRESSIVE MULTIPLE SCLEROSIS
    This decision follows authorizations received from several European countries, including the French Agency (ANSM).
  • This is a randomized, double-blind, Phase 3 study to evaluate the safety and efficacy of masitinib 4.5 mg/kg/day in patients with primary progressive multiple sclerosis (PPMS) or non-active secondary progressive multiple sclerosis (nSPMS).
  • The primary endpoint of the study is the effect of masitinib on time to confirmed disability progression.
  • Efficacy and Safety of Masitinib in Progressive Forms of Multiple Sclerosis: A Randomized, Phase 3, Clinical Trial.

Vicks® PURE Zzzs Kidz and Sleep in Heavenly Peace partner to help children get better sleep

Retrieved on: 
Friday, December 9, 2022

Vicks PURE Zzzs Kidz is aiding the work of over 300 Sleep in Heavenly Peace (SHP) chapters across the US to help communities and people most in need get better sleep.

Key Points: 
  • Vicks PURE Zzzs Kidz is aiding the work of over 300 Sleep in Heavenly Peace (SHP) chapters across the US to help communities and people most in need get better sleep.
  • View the full release here: https://www.businesswire.com/news/home/20221209005452/en/
    SHP and Vicks PURE Zzzs Kidz believe every child deserves a good night's sleep.
  • Vicks PURE Zzzs Kidz is proud to support SHPs efforts to deliver top-notch beds, providing education and resources to families in need, so every child can get better sleep.
  • If youd like to know more about how you can get involved with SHPs Deliveries Across America, please visit Deliveries Across America - Sleep in Heavenly Peace (shpbeds.org)
    Consistent, restful sleep is essential for a childs health and well-being, and Vicks PURE Zzzs Kidz is your partner in better sleep.

Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Celebrates Successful Sponsorship of 2022 XII Latin American Congress of Epilepsy in Medellin, Colombia

Retrieved on: 
Thursday, October 20, 2022

HempMeds Mexicos involvement in the industry-sponsored satellite symposia played an important role in complementing the main conference programs.

Key Points: 
  • HempMeds Mexicos involvement in the industry-sponsored satellite symposia played an important role in complementing the main conference programs.
  • Raul Elizalde, CEO of HempMeds, said in a statement: We are humbled to have been in a position to support the XII Latin American Congress of Epilepsy as a sponsor.
  • Medical Marijuana, Inc.'s headquarters are in San Diego, California, and additional information is available at OTCMarkets.com or by visiting www.medicalmarijuanainc.com .
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Subsidiary HempMeds® Mexico Participates in Research Finding Promising Therapeutic Benefits of CBD in Parkinson's Disease Treatment

Retrieved on: 
Wednesday, October 12, 2022

"In our model, we studied the effect of CBD administered to mice that were in a parkinsonian state.

Key Points: 
  • "In our model, we studied the effect of CBD administered to mice that were in a parkinsonian state.
  • To ensure the most scientifically reliable, valid, and trustworthy results, HempMeds provided its flagship RSHO-X 5,000 to aid in the studys execution.
  • "Our commitment is to provide free access to non-psychoactive cannabis and its benefits, said Raul Elizalde, CEO of HempMeds.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Medical Marijuana, Inc. Enters Into Asset Purchase Agreement With MFINITY Global LLC; Appoints MFINITY President as Kannaway President

Retrieved on: 
Tuesday, October 4, 2022

Additionally, Bill Andreoli, the President of MFINITY Global will become the President of Medical Marijuana, Inc. subsidiary, Kannaway, LLC.

Key Points: 
  • Additionally, Bill Andreoli, the President of MFINITY Global will become the President of Medical Marijuana, Inc. subsidiary, Kannaway, LLC.
  • MFINITY products will be marketed and sold exclusively under the Kannaway brand and are now available for sale through Kannaway independent distributors and on Kannaway.com.
  • The asset purchase aligns with Medical Marijuana Inc.s newly implemented growth model of expansion via acquisition.
  • Medical Marijuana, Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act.

Eisai Presents Results of Post Hoc Analysis of Eribulin Mesylate (HALAVEN) at the European Society for Medical Oncology (ESMO) Congress 2022

Retrieved on: 
Monday, September 12, 2022

These data were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22), held virtually and in-person in Paris, France from September 9-13, 2022.

Key Points: 
  • These data were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22), held virtually and in-person in Paris, France from September 9-13, 2022.
  • HER2-low tumors express low amounts of the HER2 protein, but not enough to be considered HER2-positive.
  • HER2-low is defined as an IHC of 1+ or 2 with a negative ISH.
  • Of those patients, about 60% would now be considered to have the HER2-low subtype.